{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:35:01Z","timestamp":1753893301215,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To investigate the efficacy and safety of bevacizumab combined with pemetrexed in the treatment of recurrent and metastatic cervical cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data of 65 patients with recurrent and metastatic cervical cancer who were admitted to our hospital were collected for retrospective analysis. All patients were administered with bevacizumab combined with pemetrexed for 4\u20136 cycles (21 days as 1 cycle). The short-term clinical efficacy and adverse reactions were compared between the two groups. In addition, the survival status of patients was followed up and recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At least 4 cycles of chemotherapy were given to the 65 patients. There were 0 cases of complete response (CR), 14 cases of partial response (PR), 36 cases of stable disease (SD) and 15 cases of progressive disease (PD). The objective response rate (ORR) and the disease control rate (DCR) were 21.5% (14\/65) and 76.9% (50\/65), respectively. DCR was superior in patients with squamous cell carcinoma to that in those with adenocarcinoma (<jats:italic>p\u2009<\/jats:italic>=\u20090.039), but no statistically significant difference was found in ORR. Patients with extra-pelvic metastatic lesions had a better efficacy than those with intra-pelvic metastatic lesions, but the difference was not statistically significant (<jats:italic>p\u2009<\/jats:italic>&amp;gt;\u20090.05). The post-treatment adverse reactions mainly involved fatigue, nausea and vomiting, bleeding, leukopenia, anemia, thrombocytopenia, transaminase elevation, hypertension, proteinuria and neurotoxicity, most of which were grade I\u2013II that ameliorated after symptomatic therapy. Grade III adverse reactions mainly included pain in 5 cases (7.7%), leukopenia in 17 cases (26.2%), anemia in 22 cases (33.8%), thrombocytopenia in 6 cases (9.2%), hypertension in 5 cases (7.7%) and neurotoxicity in 7 cases (10.8%). The follow-up results manifested that median overall survival (OS) and median progression-free survival (PFS) were 10.6 months and 6.6 months, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Bevacizumab combined with pemetrexed exhibits certain efficacy in the treatment of recurrent and metastatic cervical cancer, with tolerable adverse reactions. Therefore, this therapeutic option deserves clinical popularization and application.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.908101","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:21:48Z","timestamp":1652685708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Ying","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangshuang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianlong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","first-page":"320","article-title":"Cervical cancer: screening, diagnosis and staging","volume":"21","author":"Tsikouras","year":"2016","journal-title":"J Buon"},{"key":"B2","first-page":"350","article-title":"Anti-angiogenesis therapy in gynecologic malignancies","volume":"29","author":"Liu","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/j.cllc.2017.01.002","article-title":"Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial","volume":"18","author":"Park","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1457597","DOI":"10.1080\/2162402X.2018.1457597","article-title":"A single centre phase II trial to assess the immunological activity of TroVax(R) plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial","volume":"7","author":"Lester","year":"2018","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.NPR.0000490390.43604.5f","article-title":"Cervical cancer: screening, management, and prevention","volume":"41","author":"Wuerthner","year":"2016","journal-title":"Nurse Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.7150\/jca.7963","article-title":"Emerging biological treatments for uterine cervical carcinoma","volume":"5","author":"Vici","year":"2014","journal-title":"J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jnma.2020.03.002","article-title":"A review of cervical cancer: incidence and disparities","volume":"112","author":"Buskwofie","year":"2020","journal-title":"J Natl Med Assoc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ygyno.2006.03.023","article-title":"Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer","volume":"103","author":"Wright","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.6004\/jnccn.2020.0027","article-title":"NCCN guidelines insights: cervical cancer, version 1.2020","volume":"18","author":"Abu-Rustum","year":"2020","journal-title":"J Natl Compr Cancer Network"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.7314\/apjcp.2015.16.11.4791","article-title":"Study of pemetrexed-based chemotherapy for patients with locally advanced or metastatic cancers","volume":"16","author":"Qian","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1248\/bpb.b15-00435","article-title":"Pemetrexed-induced rash may be prevented by supplementary corticosteroids","volume":"38","author":"Sakurada","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2008.03.009","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller","year":"2008","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.908101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:21:52Z","timestamp":1652685712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.908101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":19,"alternative-id":["10.3389\/fsurg.2022.908101"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.908101","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"908101"}}